Navigation Links
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Date:11/9/2007

ng innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements, including summary statements relating to the interim or preliminary results of clinical trials involving Amrubicin. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the final results to differ significantly from the results summarized by such statements. Preliminary results may not be confirmed upon final analysis of the detailed results of a trial and additional information relating to the safety, efficacy or tolerability of Amrubicin may be discovered upon further analysis of clinical trial data and upon review and analysis of additional clinical trial data from this or other clinical trials. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in Pharmion's other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. Pharmion also disclaims any duty to comment upon or correct information that may be contained in reports published by the inves
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
7. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
8. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
9. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
10. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
11. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Decision Resources Group finds that ... U.S. Food and Drug Administration,s (FDA) approval of Vifor ... which was approved by the FDA in November 2013 ... (CKD) patients on dialysis. Other key findings ... Q2 2014 : ...
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... 15, 2014 AARP Foundation today announced it has established ... from the severe cold weather that has gripped much of ... those in need; so to support these emergency relief efforts ... $250,000, which could mean up to $500,000 in aid. The ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... Medical Group,s (FMG) subsidiaries, VasoStar Inc., Mentor, Ohio  today ... Frontier grant to further develop and commercialize a novel ... Occlusions (CTOs), in lieu of invasive open heart surgery ... VasoStar,s primary clinical development partner is the Cleveland ...
... July 20, 2011 Advanced Health Media (AHM), the ... solutions for the pharmaceutical industry, has named James Burgess ... assumes responsibility from Jeff Brady who has served as ... as its President for 9 years. James brings over ...
Cached Medicine Technology:Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant 2Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant 3Advanced Health Media Announces New CEO 2
(Date:7/12/2014)... Dubai, United Arab Emirates (PRWEB) July 12, 2014 ... yet another Los Angeles basketball legend is heading to ... leading scorer and six-time champion will be in the ... Health & Fitness Weekend in support of diabetes awareness. ... Events, an award-winning entertainment marketing and event management company ...
(Date:7/12/2014)... 12, 2014 Restore My Vision Today ... Samantha Pearson, a couple boasting very impressive credentials on ... My Vision Today as a way to help consumers ... become in their respective patients’ treatments . ... a “secret” trove of pertinent information relevant to eye ...
(Date:7/12/2014)... 12, 2014 Ladies, it doesn't matter what ... Those who are looking for an affordable gown can ... occasion dresses) to get their dream items. Recently, the company ... length gowns . Along with that, it is also providing ... the special offer; the deadline of this promotion is July ...
(Date:7/11/2014)... (PRWEB) July 12, 2014 According ... the total market is expected to register a ... 2019. , Browse 71 market data tables and ... TOC on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , ... report., http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides ...
(Date:7/11/2014)... FRIDAY, July 11, 2014 (HealthDay News) -- Reducing the ... incidence of Lyme disease and other tick-borne infections ... that deer populations can be manipulated to reduce human ... of contracting Lyme disease," the researchers wrote. White-tailed ... which transmit Lyme disease to people. The study ...
Breaking Medicine News(10 mins):Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4
... Frontotemporal dementia and amyotrophic lateral sclerosis, also known as Lou ... -- are triggered by a common mutation in many cases, ... gene. In the study, reported in the September 21 ... discovery of a genetic mutation that is accountable for almost ...
... caring for aging or disabled individuals in California are under ... even greater burdens, given recent cuts in state support for ... of a new policy brief by the UCLA Center for ... California,s estimated 6 millionplus informal caregivers of all ages and ...
... , WEDNESDAY, Sept. 21 (HealthDay News) -- Exposure to ... boost the risk for experiencing a heart attack, new ... risk is short-lived, the study team noted, lasting for ... entirely thereafter. What,s more, air pollution exposure may ...
... Acta Obstetricia et Gynecologica Scandinavica (AOGS) reveals ... emergency and elective cesarean sections, even after psychological counseling. ... lifetime among the approximately 3% of women who in ... of childbirth. , Led by Professor Gunilla Sydsjo of ...
... bloodstream, break into your brain and prompt behavioral changes ... more than half the world,s population, and most people,s ... recently discovered how T. gondii evades our ... known parasite to control its host,s immune system. Immunologists ...
... administration after experiencing a traumatic event blocks the development ... to a new study conducted at the University of ... "We found that there is a ,window of ... symptoms simulating PTSD in rats," said Dr. Irit Akirav ...
Cached Medicine News:Health News:A gene for Lou Gehrig's disease and frontotemporal dementia identified 2Health News:A gene for Lou Gehrig's disease and frontotemporal dementia identified 3Health News:Stressed and strapped: Caregivers for friends, relatives suffer emotional and financial strain 2Health News:Stressed and strapped: Caregivers for friends, relatives suffer emotional and financial strain 3Health News:Traffic Pollution May Raise Short-Term Heart Attack Risk 2Health News:Researchers discover how 'promiscuous parasites' hijack host immune cells 2Health News:Researchers discover how 'promiscuous parasites' hijack host immune cells 3Health News:Marijuana administration after a traumatic experience prevents post-traumatic stress symptoms 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: